Jelle Wesseling

22.2k total citations
281 papers, 10.7k citations indexed

About

Jelle Wesseling is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, Jelle Wesseling has authored 281 papers receiving a total of 10.7k indexed citations (citations by other indexed papers that have themselves been cited), including 182 papers in Cancer Research, 148 papers in Oncology and 70 papers in Molecular Biology. Recurrent topics in Jelle Wesseling's work include Breast Cancer Treatment Studies (146 papers), HER2/EGFR in Cancer Research (63 papers) and Breast Lesions and Carcinomas (59 papers). Jelle Wesseling is often cited by papers focused on Breast Cancer Treatment Studies (146 papers), HER2/EGFR in Cancer Research (63 papers) and Breast Lesions and Carcinomas (59 papers). Jelle Wesseling collaborates with scholars based in Netherlands, United States and Germany. Jelle Wesseling's co-authors include Emiel J. Rutgers, John Hilkens, Sjoerd Rodenhuis, Esther H. Lips, Marie-Jeanne T. F. D. Vrancken Peeters, Claudette E. Loo, Sabine C. Linn, Marc J. van de Vijver, Marieke E. Straver and Kenneth G. A. Gilhuijs and has published in prestigious journals such as Nature, Nature Communications and Nature Genetics.

In The Last Decade

Jelle Wesseling

271 papers receiving 10.4k citations

Peers

Countries citing papers authored by Jelle Wesseling

Since Specialization

Citations

This map shows the geographic impact of Jelle Wesseling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jelle Wesseling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jelle Wesseling more than expected).

Fields of papers citing papers by Jelle Wesseling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jelle Wesseling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jelle Wesseling. The network helps show where Jelle Wesseling may publish in the future.

Co-authorship network of co-authors of Jelle Wesseling

This figure shows the co-authorship network connecting the top 25 collaborators of Jelle Wesseling. A scholar is included among the top collaborators of Jelle Wesseling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jelle Wesseling. Jelle Wesseling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Deep learning for predicting invasive recurrence of ductal carcinoma in situ: leveraging histopathology images and clinical features 2025 ·EBioMedicine ·(unknown), Esther H. Lips, (unknown), Lennart Mulder, (unknown), (unknown), (unknown), (unknown), (unknown), Elinor J. Sawyer, Alastair M. Thompson, Sarah E. Pinder, Clara I. Sá‎nchez, Jonas Teuwen, Jelle Wesseling, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
2	Notification of locoregional breast cancer recurrence based on pathology reports: A nationwide validation study with the Netherlands Cancer Registry 2025 ·Cancer Epidemiology ·Marissa C. van Maaren, Quirinus J.M. Voorham, (unknown), Linda de Munck, Jelle Wesseling, Otto Visser, Sabine Siesling	1
3	Deintensification of Radiotherapy Use in Treatment of Ductal Carcinoma In Situ in the Netherlands–A Nationwide Overview From 2008 Until 2022 2024 ·Clinical Oncology ·(unknown), Maurice J.C. van der Sangen, Marissa C. van Maaren, John H. Maduro, Luc J. A. Strobbe, Mieke J. Aarts, (unknown), Jelle Wesseling, (unknown), H. Struikmans, Sabine Siesling	0
4	Proteomics on malignant pleural effusions reveals ERα loss in metastatic breast cancer associates with SGK1 – NDRG1 deregulation 2023 ·Molecular Oncology ·Isabel Mayayo‐Peralta, (unknown), Stefan Preković, Karianne Schuurman, (unknown), Mathilde M. Almekinders, Joyce Sanders, Cathy B. Moelans, (unknown), Jelle Wesseling, P. J. van Diest, Rui Henrique, Cármen Jerónimo, Maarten Altelaar, Wilbert Zwart	5
5	Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance 2022 ·npj Breast Cancer ·Marlous Hoogstraat, Esther H. Lips, Isabel Mayayo‐Peralta, Lennart Mulder, Petra Kristel, Ingrid van der Heijden, Stefano Annunziato, Maartje van Seijen, Petra M. Nederlof, Gabe S. Sonke, Wilbert Zwart, Jelle Wesseling, Lodewyk F.A. Wessels	23
6	Prediction of Upstaging in Ductal Carcinoma in Situ Based on Mammographic Radiomic Features 2022 ·Radiology ·Rui Hou, Lars J. Grimm, Maciej A. Mazurowski, Jeffrey R. Marks, Lorraine King, Carlo C. Maley, Thomas Lynch, (unknown), Keith D. Rogers, Nicholas Stone, Matthew Wallis, Jonas Teuwen, Jelle Wesseling, E. Shelley Hwang, Joseph Y. Lo	25
7	Prediction Models and Decision Aids for Women with Ductal Carcinoma In Situ: A Systematic Literature Review 2022 ·Cancers ·(unknown), Erica A. Wilthagen, Frederieke van Duijnhoven, (unknown), Ellen Verschuur, Thomas Lynch, Rinaa S. Punglia, Elizabeth Hwang, Jelle Wesseling, Marjanka K. Schmidt, Eveline M. A. Bleiker, Ellen G. Engelhardt	8
8	Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast 2021 ·British Journal of Cancer ·Maartje van Seijen, Esther H. Lips, Liping Fu, Daniele Giardiello, Frederieke van Duijnhoven, Linda de Munck, Lotte E. Elshof, Alastair M. Thompson, Elinor J. Sawyer, Marc D. Ryser, E. Shelley Hwang, Marjanka K. Schmidt, Paula H.M. Elkhuizen, Jelle Wesseling, Michael Schaapveld	11
9	The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review 2020 ·The Breast ·(unknown), Ellen G. Engelhardt, Frederieke van Duijnhoven, Maartje van Seijen, Patrick A. Bhairosing, Donna Pinto, Deborah Collyar, Elinor J. Sawyer, Shelley Hwang, Alastair M. Thompson, Jelle Wesseling, Esther H. Lips, Marjanka K. Schmidt	2
10	Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer 2020 ·npj Breast Cancer ·Daniele Giardiello, Iris Kramer, Maartje J. Hooning, Michael Hauptmann, Esther H. Lips, Elinor J. Sawyer, Alastair M. Thompson, Linda de Munck, Sabine Siesling, Jelle Wesseling, Ewout W. Steyerberg, Marjanka K. Schmidt	10
11	Predictors of an Invasive Breast Cancer Recurrence after DCIS: A Systematic Review and Meta-analyses 2019 ·Cancer Epidemiology Biomarkers & Prevention ·Lindy L. Visser, Emma J. Groen, Flora E. van Leeuwen, Esther H. Lips, Marjanka K. Schmidt, Jelle Wesseling	44
12	Proteomic profiling of extracellular vesicles allows for human breast cancer subtyping 2019 ·Communications Biology ·(unknown), (unknown), (unknown), Marte C. Liefaard, Esther H. Lips, Jelle Wesseling, Wei Wu, Maarten Altelaar	173
13	Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore 2019 ·Clinical Cancer Research ·Tessa G. Steenbruggen, Maartje van Seijen, (unknown), Mette S. van Ramshorst, Erik van Werkhoven, (unknown), Jelle Wesseling, Esther H. Lips, Gabe S. Sonke	16
14	Enrichment of high-grade tumors in breast cancer gene expression studies 2017 ·Breast Cancer Research and Treatment ·Maartje van Seijen, Antien L. Mooyaart, Lennart Mulder, Marlous Hoogstraat, Caroline A. Drukker, Claudette E. Loo, (unknown), Gabe S. Sonke, Jelle Wesseling, Esther H. Lips	4
15	Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes 2017 ·PLoS ONE ·Alexander Schmitz, (unknown), Kenneth E. Pengel, Claudette E. Loo, Wouter V. Vogel, Jelle Wesseling, Emiel J. Rutgers, Renato A. Valdés Olmos, Gabe S. Sonke, Sjoerd Rodenhuis, Marie Jeanne T. F. D. Vrancken Peeters, Kenneth G. A. Gilhuijs	14
16	BRCA1 -Mutated Estrogen Receptor–Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency 2016 ·Clinical Cancer Research ·Esther H. Lips, (unknown), (unknown), Lennart Mulder, Gabe S. Sonke, Lizet E. van der Kolk, Jelle Wesseling, Frans B.L. Hogervorst, Petra M. Nederlof	15
17	High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1 -like Breast Cancer 2015 ·Molecular Cancer Therapeutics ·Philip C. Schouten, Marieke A. Vollebergh, Mark Opdam, (unknown), Martin Lodén, Jelle Wesseling, Michael Hauptmann, Sabine C. Linn	43
18	Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach 2015 ·Breast Cancer Research and Treatment ·Tim Dekker, (unknown), Gerrit K. Hooijer, Sybren L. Meijer, Jelle Wesseling, James E. Boers, Ed Schuuring, Joost Bart, Joost van Gorp, Peter Bult, Sietske A. Riemersma, Carolien H. M. van Deurzen, Hein F.B.M. Sleddens, Wilma E. Mesker, Judith R. Kroep, Vincent T.H.B.M. Smit, Marc J. van de Vijver	16
19	Non-invasive longitudinal imaging of tumor progression using an 111Indium labeled CXCR4 peptide antagonist 2011 ·European Journal of Nuclear Medicine and Molecular Imaging ·Tessa Buckle, Nynke S. van den Berg, Joeri Kuil, Anton Bunschoten, Joppe Oldenburg, Alexander D. Borowsky, Jelle Wesseling, R. Irene Masada, Shinya Oishi, Nobutaka Fujii, Fijs W. B. van Leeuwen	7
20	Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy 2010 ·Annals of Oncology ·Esther H. Lips, Lennart Mulder, Juliane Hannemann, Nadja Laddach, Marie-Jeanne T. F. D. Vrancken Peeters, Marc J. van de Vijver, Jelle Wesseling, Petra M. Nederlof, Sjoerd Rodenhuis	60

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact